On March 28, 2018 -Checkmate Pharmaceuticals (Checkmate), a clinical-stage biopharmaceutical company focused on developing novel approaches for cancer immunotherapy, reported that it will present data at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place in Chicago from April 14 – April 18 (Press release, Checkmate Pharmaceuticals, 28 28, 2018, View Source(AACR)+Annual+Meeting&oq=Checkmate+Pharmaceuticals+to+Present+Data+at+the+2018+American+Association+for+Cancer+Research+(AACR)+Annual+Meeting&aqs=chrome..69i57j69i60.3354j0j7&sourceid=chrome&ie=UTF-8 [SID1234525042]). Data on Checkmate’s Phase 1b trial in subjects with advanced melanoma will be presented in an oral presentation in the Clinical Trials Plenary Session CTPL04 – Novel Immuno-oncology Strategies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation Details:

Title: Intratumoral Toll-Like Receptor 9 (TLR9) Agonist, CMP-001, In Combination With Pembrolizumab Can Reverse Resistance To PD-1 Inhibition In A Phase 1b Trial In Subjects With Advanced Melanoma
Abstract No: 10610
Presentation Number: CT144
Date/Time: April 17, 2018; 10:30 AM
Location: North Hall C, McCormick Place North (Level 1)